WO2007054717A3 - STAUROSPORINE DERIVATIVES FOR THE TREATMENT OF LEUKEMIA CHARACTERISED BY A SPTBNl -FLT3 MUTATION - Google Patents

STAUROSPORINE DERIVATIVES FOR THE TREATMENT OF LEUKEMIA CHARACTERISED BY A SPTBNl -FLT3 MUTATION Download PDF

Info

Publication number
WO2007054717A3
WO2007054717A3 PCT/GB2006/004210 GB2006004210W WO2007054717A3 WO 2007054717 A3 WO2007054717 A3 WO 2007054717A3 GB 2006004210 W GB2006004210 W GB 2006004210W WO 2007054717 A3 WO2007054717 A3 WO 2007054717A3
Authority
WO
WIPO (PCT)
Prior art keywords
flt3
treatment
leukemia
sptbnl
translocation
Prior art date
Application number
PCT/GB2006/004210
Other languages
French (fr)
Other versions
WO2007054717A2 (en
Inventor
Nicholas Cross
Francis Hector Grand
Original Assignee
Univ Southampton
Nicholas Cross
Francis Hector Grand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southampton, Nicholas Cross, Francis Hector Grand filed Critical Univ Southampton
Publication of WO2007054717A2 publication Critical patent/WO2007054717A2/en
Publication of WO2007054717A3 publication Critical patent/WO2007054717A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to the use of STAUROSPORINES DERIVATIVES for the preparation of a drug for the treatment of diseases involving SPTBN1-FLT3 translocation- modulated signalling pathways and / or SPTBN 1-FLT3 translocation gene product, especially for the curative and/or prophylactic treatment of myeloid leukemia, including especially atypical chronic myeloid leukemia, and to a method of treating diseases involving SPTBN1-FLT3 translocation-modulated signalling pathways and / or SPTBN1-FLT3 translocation gene product.
PCT/GB2006/004210 2005-11-10 2006-11-10 STAUROSPORINE DERIVATIVES FOR THE TREATMENT OF LEUKEMIA CHARACTERISED BY A SPTBNl -FLT3 MUTATION WO2007054717A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0522932.3 2005-11-10
GBGB0522932.3A GB0522932D0 (en) 2005-11-10 2005-11-10 PKC412 in treatment of atypical chronic myeloid leukemia

Publications (2)

Publication Number Publication Date
WO2007054717A2 WO2007054717A2 (en) 2007-05-18
WO2007054717A3 true WO2007054717A3 (en) 2007-08-02

Family

ID=35516689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/004210 WO2007054717A2 (en) 2005-11-10 2006-11-10 STAUROSPORINE DERIVATIVES FOR THE TREATMENT OF LEUKEMIA CHARACTERISED BY A SPTBNl -FLT3 MUTATION

Country Status (2)

Country Link
GB (1) GB0522932D0 (en)
WO (1) WO2007054717A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11382919B2 (en) 2017-11-30 2022-07-12 Albert Einstein College Of Medicine Prevention and treatment of viral infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086311A1 (en) * 1996-10-18 2002-07-04 Takara Shuzo Co., Ltd. Nucleic acid encoding receptor type protein kinase
WO2003037347A1 (en) * 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2005014004A1 (en) * 2003-08-08 2005-02-17 Novartis Ag Combinations comprising staurosporines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086311A1 (en) * 1996-10-18 2002-07-04 Takara Shuzo Co., Ltd. Nucleic acid encoding receptor type protein kinase
WO2003037347A1 (en) * 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2005014004A1 (en) * 2003-08-08 2005-02-17 Novartis Ag Combinations comprising staurosporines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 60A, ISSN: 0006-4971 *
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 568A - 569A, ISSN: 0006-4971 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2004 (2004-11-01), KERN WOLFGANG ET AL: "Identification of biologically distinct and clinically relevant subentities in patients with acute myeloid leukemia and normal karyotypes by use of gene expression profiling", XP002428153, Database accession no. PREV200510268168 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), GRAND FRANCIS H ET AL: "SPTBNI-FLT3 in atypical chronic myeloid leukemia transforms Ba/F3 cells to IL-3 independence and is sensitive to both tyrosine kinase inhibitors and immunotherapy", XP002428062, Database accession no. PREV200600184379 *
STONE RICHARD M ET AL: "Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.", BLOOD 1 JAN 2005, vol. 105, no. 1, 1 January 2005 (2005-01-01), pages 54 - 60, XP002428058, ISSN: 0006-4971 *
WEISBERG ELLEN ET AL: "Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.", CANCER CELL JUN 2002, vol. 1, no. 5, June 2002 (2002-06-01), pages 433 - 443, XP002428059, ISSN: 1535-6108 *

Also Published As

Publication number Publication date
GB0522932D0 (en) 2005-12-21
WO2007054717A2 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
WO2008113469A8 (en) Substituted imidazopyrimidines and triazolopyrimidines
HK1146485A1 (en)
WO2008104306A3 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
IL191160A (en) Use of pyrido[2,3-b]pyrazin-6-yl urea derivatives for preparation of medicaments for treating diseases mediated by inhibition of pi3k enzyme
WO2006099943A8 (en) Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2006018184A3 (en) Spirocyclic cyclohexane derivatives
TW200604182A (en) Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
WO2004071382A3 (en) Substituted heterocycles
TW200628473A (en) Novel heterocycles
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
WO2006023843A3 (en) Novel heterocycles
HK1093729A1 (en) Substituted quinolones
WO2007109799A3 (en) Polymorphs of eszopiclone malate
WO2006089664A3 (en) Heterocyclylamide-substituted imidazoles
WO2008116663A3 (en) Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents
TW200621799A (en) Acylated nonadepsipeptides II
MXPA05013200A (en) Staurosporine derivatives for hypereosinophilic syndrome.
HK1110782A1 (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroqe inoline derivatives as medicaments for the treatment of infertility
WO2005118613A3 (en) Antibacterial amide macrocycles
WO2005092062A3 (en) Compounds for neurodegenerative disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06808503

Country of ref document: EP

Kind code of ref document: A2